Why it matters: The Swiss drugmaker is buying access to a discovery platform, with Defand tasked with finding molecules against multiple disease targets. The approach could help Roche reach proteins that conventional drugs struggle to address.
The deal: Hangzhou-based Defand will use its screening platform to identify molecular glue degraders and advance programs to agreed R&D stages. Roche will then take over further preclinical and clinical development and hold exclusive global commercialization rights.
- Defand will receive an upfront payment and could earn milestones and tiered royalties on net sales. Roche also has an option to expand the collaboration to additional targets.
- Neither company disclosed financial amounts in Defand’s announcement (in Chinese). Endpoints News reported an upfront payment of less than $10 million (€9 million) and a potential total near $1 billion, citing a source familiar with the terms. Most of that reported value would therefore depend on future milestones.
How it works: Molecular glue degraders bring a target protein into contact with an E3 ubiquitin ligase, part of the cell’s protein disposal machinery. This interaction marks the target for destruction, removing the protein rather than simply blocking its activity.
- Defand, founded in 2023, says its platform can screen cytoplasmic, nuclear, transmembrane and viral proteins. It has established screening cell lines for more than 100 clinically relevant targets and built compound libraries focused on several E3 ligases.
- “The platform enables large-scale parallel screening across dozens of targets, substantially accelerating the discovery of MGDs,” Defand’s chief operating officer Huanwei Ru said in the announcement, translated from Chinese.
The big picture: The agreement is Roche’s fourth China collaboration in seven weeks. The Swiss drugmaker has also partnered with DualityBio on antibody-drug conjugates, Simcere on T-cell engagers and Earendil on bispecific antibodies.
- The big pharma’s appetite for dealmaking seems insatiable lately, as it also signed pacts with two U.S. startups, Dualitas Therapeutics and Atavistik Bio last month.
What to watch: The announcement does not identify the selected targets, specify the development milestones that trigger a handoff to Roche or give a timeline for entering clinical trials. The next meaningful test will be whether Defand’s screening platform produces candidates ready to move beyond discovery.
Sign up for our newsletter!
